Product Jurisdiction
Establishes how FDA determines which Center has primary jurisdiction over a product, using the primary mode of action, and sets out the Request for Designation procedure by which a sponsor obtains a formal determination when the classification is unclear.
What this does not cover
stated in the document's own scope- It assigns the lead review centre; it does not set GMP or postmarketing requirements for combination products, which are in 21 CFR Part 4.
- A designation does not prevent the lead centre from consulting other centres, and FDA may still require separate applications for constituent parts in appropriate cases.
- It is US law only; the EU and other jurisdictions classify drug-device combinations under their own instruments.
Always verify against the current published text before relying on it for a submission or inspection.
Overview
21 CFR Part 3 sets out how FDA decides which of its centres has primary jurisdiction over the premarket review and regulation of a combination product — a product made of two or more regulated components (drug and device, biologic and device, drug and biologic, or all three) — or of any product whose assignment is unclear or disputed. The test is the product’s primary mode of action: the single mode of action that provides the most important therapeutic action. Part 3 also sets out the Request for Designation process through which a sponsor asks FDA to make that decision before filing an application.
Scope & applicability
Products whose regulatory classification is not self-evident — combination products, and any article that could be a drug, device, or biological product depending on how its principal intended effect is achieved. It decides the Center and therefore the entire downstream regime; it does not itself impose manufacturing requirements, which come from 21 CFR Part 4 and the constituent-part regulations.
Legal basis & how it acquires force
Part 3 is a binding FDA regulation in Title 21 of the Code of Federal Regulations, originally published at 56 FR 58756 on 21 November 1991 and amended several times since. Its purpose section ties it to section 503(g) of the Federal Food, Drug, and Cosmetic Act, added by the Safe Medical Devices Act of 1990 and amended by the Medical Device User Fee and Modernization Act of 2002. It describes itself as relating to agency management and organisation: it assigns the reviewing centre and does not by itself set the premarket requirements a product must meet.
Document structure
| Part | Covers |
|---|---|
| §§ 3.1–3.3 — Purpose, definitions and scope | The four kinds of combination product, and the definitions of mode of action and primary mode of action |
| § 3.4 — Designated agency component | Assignment by primary mode of action, and the fallback algorithm where no single mode of action clearly predominates |
| §§ 3.5–3.6 — Identifying the component and the product jurisdiction officer | The intercenter agreements and the Office of Combination Products as the designated product jurisdiction officer |
| §§ 3.7–3.8 — Request for designation and letter of designation | What a sponsor files, the 15-page limit, the 60-day decision period and reconsideration |
| §§ 3.9–3.10 — Effect of designation and stay of review time | When a designation can change, and how a jurisdiction review pauses other review clocks |
Key requirements
- Classification driven by the primary mode of action — the single mode of action expected to make the greatest contribution to the overall intended therapeutic effect
- Request for Designation as the formal route to a binding jurisdictional determination
- Defined FDA response period following a complete Request for Designation
- Assignment of an agency component with primary jurisdiction, and of consulting components
Implementation tips
- Reason the classification from the intended use and mechanism actually claimed, not from a competitor product that looks similar — the claim is what FDA reads
- Where the primary mode of action is genuinely uncertain, a Request for Designation is cheaper than discovering the answer at submission
International alignment
Part 3 decides who reviews a combination product; 21 CFR Part 4 decides how it is regulated after that, setting the current good manufacturing practice requirements for combination products in Subpart A and postmarketing safety reporting in Subpart B. The designated centre then applies the premarket pathway it administers — the applications § 3.2(l) lists include an IND, IDE, NDA, BLA, 510(k) premarket notification and PMA — and can consult the other centres or, in appropriate cases, require separate applications under § 3.4(c).
21 CFR Part 3: frequently asked questions
Quick answers to common questions about 21 CFR Part 3.
What is the primary mode of action under 21 CFR 3.2?
It is the single mode of action of a combination product that provides its most important therapeutic action — the mode of action expected to make the greatest contribution to the overall intended therapeutic effects. Part 3 recognises three types: biological product, device and drug.
How long does FDA take to answer a Request for Designation?
Under § 3.8, a request is checked for completeness within 5 working days, and the product jurisdiction officer issues a letter of designation within 60 days of the filing date. If no letter is issued in that time, the sponsor’s own recommendation becomes the designation.
What if no mode of action clearly predominates?
Section 3.4(b) assigns the product to the centre that regulates other combination products presenting similar questions of safety and effectiveness, or, if there are none, to the centre with the most expertise in the most significant safety and effectiveness questions the product raises.
Can a designation be challenged?
Yes. A sponsor may request reconsideration within 15 days of receiving the letter, in no more than 5 pages and without new information, and the product jurisdiction officer must respond in writing within 15 days.